Healthcare

Bausch Health Announces Second Quarter 2024 Results

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP…

5 months ago

OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer

ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and…

5 months ago

OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer

ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and…

5 months ago

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

5 months ago

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

5 months ago

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass.,…

5 months ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

5 months ago

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use…

5 months ago

23andMe Announces CEO’s Take-Private Proposal

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and…

5 months ago

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

Stockholders to Receive $14.30 Per Share in CashMURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM)…

5 months ago